Last reviewed · How we verify
Digoxin Alone
At a glance
| Generic name | Digoxin Alone |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) (PHASE1)
- PK/PD of Digoxin in Infants With SVHD (PHASE1, PHASE2)
- A Phase 1 Study of PROT-001. (PHASE1)
- A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis (NA)
- Effect of Estrogen Treatment on Drug Metabolism and Transport (PHASE4)
- Digoxin After Acute Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Digoxin Alone CI brief — competitive landscape report
- Digoxin Alone updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI